Home / 2014 / June (page 5)

Monthly Archives: June 2014

ADA 2014 UPDATE: SGLT2-Inhibitors

There was a lot of great information at this year’s ADA Scientific Sessions on the sodium glucose co-transporter 2 (SGLT2) inhibitors both alone and in combination with other medications, and we have a review for you. Canagliflozin  Canagliflozin has demonstrated improvement in glycemic control, body weight, and blood pressure across …

Read More »

Powerhouse Fruits and Vegetables

Powerhouse Fruits and Vegetables  What’s a "powerhouse" fruit or vegetable? According to a new study published in a Centers for Disease Control and Protection journal, they’re foods that are "most strongly associated with reduced chronic disease risk." They also contain 17 essential nutrients in quantities that constitute 10 percent or more of …

Read More »

FlexTouch® Insulin Analog Pen

FlexTouch-pen-image

FlexTouch® Insulin Analog Pen  FlexTouch® is the first and only prefilled insulin delivery device with no push-button extension and is prefilled with long-acting insulin Levemir® (insulin detemir [rDNA origin] injection). It offers several key features: as 1) Prefilled insulin pens containing 3 mL (300 units) of insulin detemir 2) Doses …

Read More »

ADA: Walkable Neighborhoods Cut Diabetes Rates

Residents of areas that encourage walking also have lower obesity rates. Those are the finding from two studies that showed those living in an area that encourages walking are also three times more likely to walk or bike and half as likely to drive to get from one place to …

Read More »

ADA: CKD Is a Type 2 Diabetes Risk Equivalent in CAD Patients

Among patients with coronary artery disease, those who have both chronic kidney disease and type 2 diabetes face a significantly increased risk of cardiovascular events, compared with those who have either condition separately. The researchers found that the risk of cardiovascular events was significantly higher in patients with type 2 …

Read More »

Are the New Guidelines for Lipids Appropriate for People with Diabetes?

The new guidelines divide patients into four groups for whom statin treatment is recommended: individuals with cardiovascular disease; individuals with LDL cholesterol (LDL-C) levels higher than 190 mg/dL; individuals with diabetes, between the ages of 40-75, with LDL-C levels 70-189 mg/dL; and individuals without diabetes or cardiovascular disease, with LDL-C …

Read More »

ADA: New HbA1c Target of 7.5% for Type 1 Children and Older Adults

Recent scientific evidence and better tools to monitor for hypoglycemia helped establish the new position statement…. Anne Peters, MD, FACP, professor at the Keck School of Medicine, University of Southern California, said during a press conference at the American Diabetes Association’s 74th Scientific Sessions, “Our goal here is to present …

Read More »